DCVC BIO
DCVC Bio is a venture capital fund that invests in early-stage life science companies driven by deep-tech approaches. Advances in genetic sequencing, artificial intelligence, and automation are converging to transform existing life sciences technologies and speed the development of new ones. The firm is looking for companies affecting deep technological change in synthetic biology, medicine, and agriculture. DCVC Bio was founded in 2018 and is based in San Francisco, California, United States.
Similar Organizations
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Current Employees Featured
Eric Shiozaki Partner @ DCVC Bio
Partner
2021-06-01
Andy May Entrepreneur In Residence @ DCVC Bio
Entrepreneur In Residence
2020-09-01
Anna Fokina Investment Director @ DCVC Bio
Investment Director
2018-04-01
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-20 | Auron Therapeutics | DCVC Bio investment in Series A - Auron Therapeutics | 48 M USD |
| 2022-07-01 | Sabanto | DCVC Bio investment in Series A - Sabanto | 17 M USD |
| 2022-04-19 | Unlearn.AI | DCVC Bio investment in Series B - Unlearn.AI | 50 M USD |
| 2022-03-08 | Creyon Bio | DCVC Bio investment in Series A - Creyon Bio | 40 M USD |
| 2022-02-23 | Plexium | DCVC Bio investment in Series B - Plexium | 102 M USD |
| 2021-12-09 | Totus Medicines | DCVC Bio investment in Series A - Totus Medicines | 40 M USD |
| 2021-10-06 | CH4 Global | DCVC Bio investment in Series A - CH4 Global | 13 M USD |
| 2021-09-23 | GenEdit | DCVC Bio investment in Series A - GenEdit | 26 M USD |
| 2021-07-19 | Frontier Medicines | DCVC Bio investment in Series B - Frontier Medicines | 88.5 M USD |
| 2021-07-15 | Stemson Therapeutics | DCVC Bio investment in Series A - Stemson Therapeutics | 15 M USD |